NMR-based metabolomics associated with chronic kidney disease in humans and animals: a one health perspective by Hunter, Elena et al.
Vol.:(0123456789) 
Molecular and Cellular Biochemistry 
https://doi.org/10.1007/s11010-021-04222-1
NMR‑based metabolomics associated with chronic kidney disease 
in humans and animals: a one health perspective
Elena Hunter1 · Benita Percival1 · Zeeshan Ahmad2 · Ming‑Wei Chang3 · John A. Hunt1 · Séverine Tasker4 · 
Luisa De Risio1,4 · Philippe B. Wilson1 
Received: 20 May 2021 / Accepted: 7 July 2021 
© The Author(s) 2021
Abstract
Chronic kidney disease (CKD) is a renal dysfunction that can lead to high rates of mortality and morbidity, particularly 
when coupled with late diagnosis. CKD has become a major health problem due to its challenging detection at early stages 
when clear symptoms are yet to be presented. Thus, CKD is likely to be identified when the substantive conditions of the 
disease are manifest. In order to address the development of the disease and provide necessary treatments at the initial stage, 
the investigation of new biomarkers and metabolites associated with early detection of CKD are needed. Identified metabolites 
could be used to confirm the presence of the disease, obtain information on its mechanism and facilitate the development of 
novel pharmaceutical treatments. Such metabolites may be detected from biofluids and tissues using a range of analytical 
techniques. There are a number of metabolites that have been identified by mass spectrometry at high sensitivities, whilst the 
detection of metabolites directly from biofluids using NMR could present a more rapid way to expand our understanding of 
this disease. This review is focused on NMR-based metabolomics associated with CKD in humans and animals.
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Introduction
Chronic kidney disease (CKD) is a progressive renal dys-
function. It raises a serious concern worldwide due to its 
challenging detection at early stages. CKD includes five 
stages calculated from either albumin or serum creatinine 
in urine. Stage one is characterised by estimated glomerular 
filtration rate (eGFR) being over 90 ml/min/1.73m2, whereas 
in stage two, eGFR is equal to 89–60 ml/min/1.73m2 [1, 2]. 
These two stages can be asymptomatic. eGFR is reduced 
to lower than 60  ml/min/1.73m2 in stage three, where 
electrolyte disorders and acid–base disbalance can also be 
observed [1]. Transplantation or dialysis are required at 
stage five due to eGFR being lower than 15 ml/min/1.73m2 
[1]. This leads to an inability of the kidneys to maintain both 
homeostasis and healthy concentrations of metabolites in 
urine and blood. In order to prevent further development of 
CKD at the early stages of the disease, metabolites that are 
accumulated in blood or urine can be identified. Moreover, 
these metabolites could also provide insight into metabolic 
pathways and mechanisms that lead to the progression of 
the disease. This identification can be carried out by a range 
of analytical techniques. The most common method for the 
investigation of metabolites as biomarkers for CKD is mass 
spectrometry. Although mass spectrometry is the most com-
mon technique for such analysis of metabolites, it has several 
disadvantages such as the requirement of substantial sample, 
analytical protocol preparation and the destructive nature of 
the technology. Therefore, the current review is focused on 
metabolites associated with CKD that can be detected using 
NMR. In addition, this review will summarise metabolites 
obtained from humans and animals to provide an insight into 
the differences and similarities of the disease within different 
groups of organisms.
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Potential biomarkers for the detection 
of CKD
The role of metabolites in the detection of kidney failure 
is manifest. As healthy kidneys have an impact on circu-
lating metabolite levels through filtration, secretion, reab-
sorption, and metabolism, in the case of kidney failure, 
metabolites that are considered to be cleared by the kidney, 
start to fluctuate in concentration in biofluids and tissues. 
Therefore, it is conceivable that the level and range of 
metabolites in readily accessible biofluids could help to 
identify CKD within its early stages.
Chen et al. analysed serum in an untargeted metabo-
lomics workflow in 2155 participants in total including 
healthy controls and patients with CKD stages from one 
to five. As a result, five metabolites associated with CKD, 
5-methoxytryptophan (5-MTP), canavanino-succinate, 
taurine, acetylcarnitine, and tiglylcarnitine, were identi-
fied in humans [3]. Such biomarkers could be detected 
at the early stage of the disease. 5-MTP was found to be 
strongly related to clinical markers for early stage identi-
fication of CKD. The level of 5-MTP, which is involved 
in endogenous tryptophan metabolism, decreases in serum 
but increases in urine with the progression of CKD [3]. 
This can be due to a reduction in reabsorption of 5-MTP 
and tryptophan in the kidney [3]. It was observed that the 
levels of canavanine and succinate were upregulated in 
blood samples of humans with CKD [4, 5].
Canavanine has a similar structure to arginine, but is a 
non-protein amino acid. If the concentration of canavanine 
is too high, the amino acid starts to accumulate in the 
blood and cells. It can affect metabolism, and inhibit the 
synthesis of proteins and immunoglobulins. Bedolla et al. 
investigated the levels of both canavanine and creatine 
in serum of human patients with CKD before and after 
dialysis [4]. It was found that the level of canavanine in 
the serum of patients with CKD ranged from 10 to 21 mg/
dl, whilst the level of creatinine was observed to be from 
3 to 14 mg/dl in the control healthy group [4]. However, 
dialysis decreased the levels of canavanine and creatinine 
to 9.5–19 and 0.9 to 7.5 mg/dl, respectively [4]. One of 
the criteria for analysis of renal function is the glomerular 
filtration rate (GFR). If GFR is decreased, albumin can 
reach urine that is adjusted by creatinine concentration. 
Therefore, a ratio of albumin-creatinine (ACR) can act as 
another indicator of CKD [2].
Disturbance of purine metabolism could also be linked 
to the progression of CKD. Such disturbances can result in 
the production of hypoxanthine and breakdown to xanthine 
and uric acid. The accumulation of uric acid in the blood 
could subsequently lead to hyperuricemia. According to 
Chuang et al., hyperuricemia occurs when the serum uric 
acid level is more than 7.0 mg/dl and more than 6.0 mg/
dl for males and females, respectively [6]. Therefore, an 
increase in levels of uric acid can be an indicator of CKD 
in humans. Animals such as cows, several species of rats, 
cats, and dogs carry an enzyme called urate oxidase in 
their liver which is capable of converting uric acid to 
allantoin [7]. However, such an enzyme was not found in 
the liver of humans and several other primates such as the 
Cynomolgus monkey [7]. This means that purine catabo-
lism ends with uric acid in humans, but, in cats and dogs, 
the final product is allantoin. However, excessive produc-
tion of reactive oxygen species might lead to the oxidation 
of uric acid to allantoin in humans [8].
Allantoin is a marker of oxidative stress which was found 
to be associated with mortality in patients with CKD [9]. 
It has been reported that the concentration of allantoin in 
plasma in human patients with chronic renal failure was 
(27.1 ± 13.8) μmol/l compared to the control concentration 
of 4.67 ± 2.99 μmol/l [10]. Yang et al. found that the level of 
allantoin increases in patients with CKD from 18 ± 13.5 μg/
ml (healthy patients) to 238 ± 57 μg/ml [11]. Allantoin from 
patients with CKD was then injected into the C57BL/6 
mouse model [11] and it was observed that mice in the treat-
ment group with allantoin had increased scratching behav-
iour compared to the control group at day 7 [11]. According 
to Yang et al. this could be because allantoin activates DRG 
neurons and therefore cause symptoms such as a pruritus 
[11]. In addition, upregulation of levels of ribothymidine and 
allantoin were also detected in rats with CKD [12].
Albumin and uromodulin were found to be associated 
with CKD [13, 14]. It has been reported that urine of healthy 
dogs contains low concentrations of albumin (3.1 ± 1.4 mg/
dl) and a high concentration of uromodulin (11.9 ± 2.3 mg/
dl), whereas the urine samples of dogs with CKD showed 
the opposite pattern, where the level of albumin increased to 
26.6 mg/dl, but the concentration of uromodulin decreased 
to near 0  mg/dl [13]. Moreover, levels of uromodulin 
decreased in the urine of human patients with CKD from 
14.17 to 1.83 mg/g but increased in serum samples of those 
patients [14]. Furthermore, Ferlizza et al. observed upregu-
lation of methylguanidine, dimethylamine, and kynurenic 
acid metabolites in the urine of dogs with CKD using NMR 
[13]. Upregulation of kynurenic acid was also detected in 
rats with CKD [12].
Metabolic dysfunction in amino acids, fatty acids, tau-
rine, choline was also observed elsewhere [15]. Fumarate 
and ribonate were upregulated in the serum of human 
patients with CKD [9]. Fumarate is involved in the citric 
acid cycle, whereas ribonate is the intermediate of the pen-
tose phosphate pathway [9]. The levels of lactate and malate 
were also increased; however, urine citrate was reduced in 
humans with CKD [5]. Moreover, it has been reported that 
an induced level of adenine was found in patients with CKD 
Molecular and Cellular Biochemistry 
1 3
[15]. A possible reason for this may be that adenine, which is 
metabolised to 2,8-dihydroxyadenine in vivo and insoluble 
in water, can affect functions of the kidney by promoting 
excretion of nitrogen compounds and influence the balance 
of electrolytes [15].
The upregulation of creatinine, fibroblast growth fac-
tor-23 (FGF-23), and SDMA were found to be associated 
with CKD in cats [16]. Serum creatinine increased from 
1.29 mg/dl of the control to 1.99 mg/dl in cats with CKD 
[17]. The levels of homocysteine, which is an amino acid in 
S-adenosyl methionine metabolism were higher in serum 
of cats with CKD compared to the control healthy group. It 
was found that levels of homocysteine increased along with 
the progression of the disease. Another study has reported 
that levels of FGF‐23 in the plasma of cats start to increase 
at the early stages of CKD [18]. Moreover, uHSP72:uCr, 
which is urinary heat shock protein-72 could be another bio-
marker for the identification of CKD in cats and dogs. It was 
observed that the levels of uHSP72:uCr were increased in 
cats and dogs with CKD [16, 19].
Other metabolites were identified to be correlated with 
CKD. For instance, high levels of betaine, leucine, trimeth-
ylamine-N-oxide, citrate methyl histidine were increased in 
serum of humans compared to a control group [20]. How-
ever, the levels of glutamine, pyruvate, valine, acetate, and 
tyrosine were downregulated in human patients with CKD 
[20]. Patients with both diabetes and CKD had decreased 
levels of urea, acetate, arginine, pyruvate, N-acetyl-glyco-
protein, creatinine, and citrate compared to patients with 
the single condition of CKD [20]. Conversely, increases in 
levels of tyrosine, valine, lactate, leucine, and choline were 
detected in patients with both diabetes and CKD compared 
to patients with CKD alone [21].
Influence of gut microbiota on CKD
The connection between gut microbiota and CKD has been 
observed elsewhere [22]. It has been found that CKD can 
result in intestinal dysbiosis that leads to the formation 
of uremic toxins such as p-cresol sulphate and indoxyl 
sulphate [22]. P-cresol sulphate and indoxyl sulphate are 
produced by gut microbiota and may lead to glomerular 
sclerosis and tubulointerstitial fibrosis [22, 23]. These tox-
ins could influence the progression of CKD. One study 
investigated a group of human patients with CKD who 
presented significantly higher levels of both p-cresol sul-
phate and indoxyl sulphate than a control group. Moreover, 
3-Indolepropionic acid (IPA), which is a product of deam-
ination of microbiota, was significantly lower in serum 
samples of humans with CKD than the control group [22]. 
IPA was found to be significantly related to CKD develop-
ment and renal function changes [22]. Therefore, a high 
level of IPA leads to a lower risk of developing CKD. This 
means that IPA could not only be an important biomarker, 
but also act as a protective agent against the disease.
Detection of metabolites using analytical 
techniques
The detection of renal function is often based on the glo-
merular filtration rate (GFR). However, it can be chal-
lenging to obtain information on CKD aetiology. Moreo-
ver, the treatment of CKD in companion animals is often 
challenging due to possible late diagnosis and progressive 
renal damage. In order to prevent further development of 
CKD at the early stages of the disease, metabolites that 
are accumulated in blood or urine need to be identified. 
Moreover, metabolites could also provide insight on meta-
bolic pathways and mechanisms that lead to the progres-
sion of the disease as well as help to develop therapies 
needed. This metabolite identification could be carried out 
by a range of analytical techniques. Table 1 summarises 
selected metabolites detected in either urine or serum of 
humans, cats, and dogs with CKD along with identifica-
tion methods used.
Mass spectroscopy (MS) and nuclear magnetic reso-
nance (NMR) are able to detect small molecules in a tar-
geted or untargeted manner. A targeted approach is focused 
on previously known metabolites, whereas the untargeted 
approach represents the analysis of all metabolites in a 
sample [26].
The identification of all metabolites in biofluids remains 
a challenge. Therefore, a combination of different analyti-
cal techniques may be a solution for such blanket identifi-
cation. Both HPLC (high-pressure liquid chromatography) 
and GC–MS (gas chromatography-mass spectroscopy) are 
sensitive techniques, but are also time-consuming as sam-
ples require additional preparation [10]. LC–MS (liquid 
chromatography-mass spectroscopy) possesses high sensi-
tivity and requires minimal sample preparation. However, 
the drawbacks of LC–MS relate to its high cost and the 
possibility of sample ion suppression. NMR possesses a 
number of advantages over these analytical techniques. 
NMR offers quantification and identification of untargeted 
metabolites, is non-destructive, and proceeds with rapid 
data analysis. Moreover, a sample does not require addi-
tional preparation for NMR analysis such as protein pre-
cipitation, dilution, and solid-phase filtration that is com-
monly needed for alternative analyses. NMR could be an 
ideal solution for analysis of urine, plasma, or serum to 
obtain information on novel or previously detected metab-
olites associated with CKD. Moreover with the recently 
demonstrated development of biofluid spectroscopy at low 
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magnetic fields, the near-patient testing potential of NMR 
is a real possibility [27].
Conclusion
It is currently a challenge to reliably detect CKD at its 
early stages in humans and animals. This could lead to 
mortality and therefore raises clinical concerns. CKD can 
be detected at the early stages using specific metabolites as 
biomarkers or signatures. There are a number of a poten-
tial biomarkers for CKD have been identified in humans 
and animals. However, some of these biomarkers need 
validation across multiple technologies. Moreover, our 
understanding of biomarkers in animals with CKD is still 
limited. Analytical techniques such as LC–MS, GC–MS 
and NMR can provide an insight into the detection of 
novel metabolites and their concentration associated with 
the early stages of CKD.
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